<DOC>
	<DOCNO>NCT00239005</DOCNO>
	<brief_summary>This open , multi-center randomize control study design investigate quality life patient mycophenolate mofetil ( MMF ) -induced gastrointestinal ( GI ) adverse event convert enteric-coated mycophenolate sodium ( EC-MPS ) .</brief_summary>
	<brief_title>Enteric-Coated Mycophenolate Sodium Quality Life Patients With Gastrointestinal Symptoms Related Mycophenolate Mofetil Therapy After Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Received kidney transplant 2 . Receiving immunosuppressive regimen include MMF 3 . Patients GI side effect standard MMF dose patient reduce dose MMF exist tolerated/controlled GI side effect . 4 . At least 18 year age 5 . Willing provide write informed consent 6 . Able meet study requirement include complete questionnaire complete four study visit . 1 . Patients GI symptom assume know cause medroxyprogesterone acetate ( MPA ) therapy ( e.g . oral bisphosphonate induce , infectious diarrhea ) 2 . Acute rejection &lt; 1 week prior study enrollment 3 . Woman childbearing potential planning become pregnant pregnant and/or lactate unwilling use effective mean contraception 4 . Presence psychiatric illness ( i.e. , schizophrenia , major depression ) , opinion site investigator , would interfere study requirement 5 . Undergoing acute medical intervention hospitalization 6 . Any medical condition , opinion site investigator base recall chart review , would interfere complete study , include , limited , visual problem cognitive impairment . 7 . Receiving investigational drug receive investigational drug within 30 day prior study enrollment . Additional protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>QoL</keyword>
	<keyword>GI Side Effects</keyword>
	<keyword>MPA</keyword>
</DOC>